MAJOR, 0.2 mg recall — The Harvard Drug Group LLC (Class II)
The Harvard Drug Group LLC is recorded by the U.S. Food and Drug Administration (FDA) as recalling MAJOR, 0.2 mg — a Class II recall, initiated 2026-06-16 and posted to the FDA enforcement report on 2026-07-01, under recall number D-0609-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Subpotent Drug”. From the product description, the form is tablets, the strength given is 0.2 mg, the package is described as 20 TABLETS (2 x 10) and it is marked Rx only. 1 National Drug Code number is printed in the record: 0904-7282-10. Distribution is recorded as “U.S. Nationwide” — Nationwide (US), with the recalling firm on record in OH, United States. It is the only recall number the FDA has filed under event ID 99240. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0609-2026 |
|---|---|
| FDA event ID | 99240 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | The Harvard Drug Group LLC |
| Recall initiated | 2026-06-16 |
| Reported by FDA | 2026-07-01 |
| Report lag | 15 days from initiation to report |
| Distribution | U.S. Nationwide. — Nationwide (US) |
| Firm location on record | OH, United States |
| Product description (source) | Carton Label: MAJOR, Methylergonovine Maleate Tablets, USP, 0.2 mg, 20 TABLETS (2 x 10), Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, in 46268, NDC 0904-7282-10. Blister Label: Methylergonovine Maleate Tablets, 0.2 mg, USP, One Tablet, Major Pharm/Indianapolis, IN 46268, NDC 0904-7282-10. |
Reason reported by FDA
Subpotent Drug
2 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
6 identifying values matched by exact pattern in the 43-word product description above; each is a literal substring of it.
| Product named | MAJOR |
|---|---|
| Form | Tablets |
| Strength | 0.2 mg |
| Package | 20 TABLETS (2 x 10) |
| NDC | 0904-7282-10 |
| Marketing category | Rx only |
| Distributed by | MAJOR PHARMACEUTICALS, Indianapolis |
Other indexed recalls from The Harvard Drug Group LLC
2 indexed records name The Harvard Drug Group LLC as the recalling firm, across 2 FDA events, reported 2026-04-29 to 2026-07-01. A coverage-limited activity count over the ingested window, not a quality rating.
| Recall record | Recall number | FDA tier | Strength / form | Reported |
|---|---|---|---|---|
| Omega-3-Acid, 1 gram | D-0493-2026 | Class II | 1 gram · Capsules | 2026-04-29 |
Reported in the same month (2026-07)
111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Fenofibrate Capsules, 200 mg | D-0611-2026 | Ajanta Pharma Usa Inc | Class II | 2026-07-01 |
| Corlanor (ivabradine) tablets, 5 mg | D-0612-2026 | Amgen, Inc. | Class II | 2026-07-01 |
| Sensipar (cinacalcet) Tablets, 30mg | D-0613-2026 | Amgen, Inc. | Class II | 2026-07-01 |
| Sensipar (cinacalcet) Tablets, 60mg | D-0614-2026 | Amgen, Inc. | Class II | 2026-07-01 |
| Corlanor (ivabradine) tablets, 7.5mg | D-0615-2026 | Amgen, Inc. | Class II | 2026-07-01 |
| Sensipar (cinacalcet) Tablets, 90mg | D-0616-2026 | Amgen, Inc. | Class II | 2026-07-01 |
| DULOXETINE D/R, 30 mg | D-0617-2026 | Direct RX | Class II | 2026-07-01 |
| Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, 1295 mL | D-0618-2026 | Central Admixture Pharmacy Services, Inc. | Class II | 2026-07-01 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 7 nearest to 2026-07-01 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| PReye Vitamin See Antioxidant Preservative Free Eye Drops | D-0621-2026 | Preye LLC | Eye Drops | 2026-07-01 |
| BD ChloraPrep Clear, 2% | D-0622-2026 | Carefusion 213, LLC | 2% · Solution | 2026-07-01 |
| BD ChloraPrep FREPP Clear, 2% | D-0623-2026 | Carefusion 213, LLC | 2% · Solution | 2026-07-01 |
| Lacosamide Tablets, 100mg | D-0626-2026 | Annora Pharma Private Ltd | 100mg · Tablets | 2026-07-01 |
| Povi-One, 10% | D-0627-2026 | Elevate Oral Care | 10% | 2026-07-01 |
| Perampanel CIII Tablets, 6mg | D-0628-2026 | Sun Pharmaceutical Industries Inc | 6mg · Tablets | 2026-07-01 |
| Alyacen 7/7/7, 0.5mg/0.035mg | D-0588-2026 | Glenmark Pharmaceuticals Inc., Usa | 0.5mg/0.035mg · Tablets | 2026-06-24 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 0904-7282-10 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); The Harvard Drug Group LLC (2 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0609-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0609-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-07-01
- Ingested
- 2026-08-22
- Record hash
7ee090ae453ff224
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.